nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Naloxone—TLR4—chronic obstructive pulmonary disease	0.0118	0.745	CrCbGaD
Naltrexone—Buprenorphine—CYP1A2—chronic obstructive pulmonary disease	0.00256	0.162	CrCbGaD
Naltrexone—OPRD1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00171	0.022	CbGpPWpGaD
Naltrexone—OPRK1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.0015	0.0193	CbGpPWpGaD
Naltrexone—Naloxone—ALB—chronic obstructive pulmonary disease	0.00147	0.093	CrCbGaD
Naltrexone—OPRM1—Opioid Signalling—PDE4A—chronic obstructive pulmonary disease	0.00146	0.0188	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A2—chronic obstructive pulmonary disease	0.00137	0.0176	CbGpPWpGaD
Naltrexone—OPRM1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00127	0.0163	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00113	0.0146	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000995	0.0128	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000992	0.0127	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.000981	0.0126	CbGpPWpGaD
Naltrexone—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000972	0.00107	CcSEcCtD
Naltrexone—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000972	0.00107	CcSEcCtD
Naltrexone—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00097	0.00107	CcSEcCtD
Naltrexone—UGT1A1—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.00097	0.0125	CbGpPWpGaD
Naltrexone—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000969	0.00107	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000967	0.00107	CcSEcCtD
Naltrexone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000966	0.00107	CcSEcCtD
Naltrexone—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000962	0.00106	CcSEcCtD
Naltrexone—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000953	0.00105	CcSEcCtD
Naltrexone—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000953	0.00105	CcSEcCtD
Naltrexone—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000953	0.00105	CcSEcCtD
Naltrexone—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000953	0.00105	CcSEcCtD
Naltrexone—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000952	0.00105	CcSEcCtD
Naltrexone—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000947	0.00104	CcSEcCtD
Naltrexone—Infection—Formoterol—chronic obstructive pulmonary disease	0.000947	0.00104	CcSEcCtD
Naltrexone—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000939	0.00104	CcSEcCtD
Naltrexone—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000939	0.00104	CcSEcCtD
Naltrexone—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000939	0.00104	CcSEcCtD
Naltrexone—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000938	0.00103	CcSEcCtD
Naltrexone—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000935	0.00103	CcSEcCtD
Naltrexone—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000935	0.00103	CcSEcCtD
Naltrexone—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000935	0.00103	CcSEcCtD
Naltrexone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000933	0.00103	CcSEcCtD
Naltrexone—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000933	0.00103	CcSEcCtD
Naltrexone—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000933	0.00103	CcSEcCtD
Naltrexone—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00093	0.00103	CcSEcCtD
Naltrexone—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00093	0.00103	CcSEcCtD
Naltrexone—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000927	0.00102	CcSEcCtD
Naltrexone—Infection—Montelukast—chronic obstructive pulmonary disease	0.000927	0.00102	CcSEcCtD
Naltrexone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000926	0.00102	CcSEcCtD
Naltrexone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000926	0.00102	CcSEcCtD
Naltrexone—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000922	0.00102	CcSEcCtD
Naltrexone—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000918	0.00101	CcSEcCtD
Naltrexone—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000917	0.00101	CcSEcCtD
Naltrexone—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000915	0.00101	CcSEcCtD
Naltrexone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000907	0.001	CcSEcCtD
Naltrexone—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000903	0.000996	CcSEcCtD
Naltrexone—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.0009	0.000993	CcSEcCtD
Naltrexone—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.0009	0.000993	CcSEcCtD
Naltrexone—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000894	0.000986	CcSEcCtD
Naltrexone—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000886	0.000977	CcSEcCtD
Naltrexone—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000885	0.000977	CcSEcCtD
Naltrexone—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000884	0.000975	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—IL17A—chronic obstructive pulmonary disease	0.000883	0.0113	CbGpPWpGaD
Naltrexone—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000882	0.000974	CcSEcCtD
Naltrexone—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000878	0.000969	CcSEcCtD
Naltrexone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000874	0.000964	CcSEcCtD
Naltrexone—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00087	0.00096	CcSEcCtD
Naltrexone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00087	0.00096	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000868	0.000958	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000868	0.000958	CcSEcCtD
Naltrexone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000862	0.000951	CcSEcCtD
Naltrexone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000862	0.000951	CcSEcCtD
Naltrexone—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000858	0.000946	CcSEcCtD
Naltrexone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000857	0.000945	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00085	0.000938	CcSEcCtD
Naltrexone—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00085	0.000937	CcSEcCtD
Naltrexone—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00085	0.000937	CcSEcCtD
Naltrexone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000847	0.000935	CcSEcCtD
Naltrexone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000847	0.000935	CcSEcCtD
Naltrexone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000844	0.000931	CcSEcCtD
Naltrexone—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000841	0.000928	CcSEcCtD
Naltrexone—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000838	0.000925	CcSEcCtD
Naltrexone—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000835	0.000922	CcSEcCtD
Naltrexone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00083	0.000916	CcSEcCtD
Naltrexone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000828	0.000914	CcSEcCtD
Naltrexone—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000826	0.000911	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000823	0.000908	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000823	0.000908	CcSEcCtD
Naltrexone—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000822	0.000906	CcSEcCtD
Naltrexone—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000822	0.000906	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00082	0.000904	CcSEcCtD
Naltrexone—UGT1A1—Phase II conjugation—CYP1A2—chronic obstructive pulmonary disease	0.000815	0.0105	CbGpPWpGaD
Naltrexone—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000815	0.000899	CcSEcCtD
Naltrexone—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000815	0.000899	CcSEcCtD
Naltrexone—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000815	0.000899	CcSEcCtD
Naltrexone—Pain—Formoterol—chronic obstructive pulmonary disease	0.000815	0.000899	CcSEcCtD
Naltrexone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000814	0.000898	CcSEcCtD
Naltrexone—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000812	0.000896	CcSEcCtD
Naltrexone—OPRM1—IL4-mediated signaling events—IL10—chronic obstructive pulmonary disease	0.000809	0.0104	CbGpPWpGaD
Naltrexone—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000808	0.000891	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000806	0.000889	CcSEcCtD
Naltrexone—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000805	0.000888	CcSEcCtD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.000804	0.0103	CbGpPWpGaD
Naltrexone—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000802	0.000885	CcSEcCtD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.0008	0.0103	CbGpPWpGaD
Naltrexone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.0008	0.000883	CcSEcCtD
Naltrexone—Pain—Montelukast—chronic obstructive pulmonary disease	0.000798	0.000881	CcSEcCtD
Naltrexone—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000798	0.00088	CcSEcCtD
Naltrexone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000796	0.000878	CcSEcCtD
Naltrexone—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000793	0.000875	CcSEcCtD
Naltrexone—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000792	0.000873	CcSEcCtD
Naltrexone—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000789	0.000871	CcSEcCtD
Naltrexone—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000789	0.00087	CcSEcCtD
Naltrexone—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000787	0.000868	CcSEcCtD
Naltrexone—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000785	0.000866	CcSEcCtD
Naltrexone—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000785	0.000866	CcSEcCtD
Naltrexone—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000784	0.000865	CcSEcCtD
Naltrexone—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000782	0.000863	CcSEcCtD
Naltrexone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000781	0.000862	CcSEcCtD
Naltrexone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000779	0.00086	CcSEcCtD
Naltrexone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000779	0.00086	CcSEcCtD
Naltrexone—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000779	0.000859	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000777	0.000857	CcSEcCtD
Naltrexone—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000776	0.000856	CcSEcCtD
Naltrexone—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000769	0.000849	CcSEcCtD
Naltrexone—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000769	0.000849	CcSEcCtD
Naltrexone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000763	0.000842	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000763	0.000842	CcSEcCtD
Naltrexone—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000757	0.000835	CcSEcCtD
Naltrexone—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000757	0.000835	CcSEcCtD
Naltrexone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000753	0.000831	CcSEcCtD
Naltrexone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000753	0.000831	CcSEcCtD
Naltrexone—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000753	0.000831	CcSEcCtD
Naltrexone—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000753	0.000831	CcSEcCtD
Naltrexone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000751	0.000828	CcSEcCtD
Naltrexone—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000745	0.000822	CcSEcCtD
Naltrexone—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000745	0.000821	CcSEcCtD
Naltrexone—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000744	0.000821	CcSEcCtD
Naltrexone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000744	0.000821	CcSEcCtD
Naltrexone—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000741	0.000818	CcSEcCtD
Naltrexone—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000741	0.000818	CcSEcCtD
Naltrexone—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00074	0.000816	CcSEcCtD
Naltrexone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000738	0.000814	CcSEcCtD
Naltrexone—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000738	0.000814	CcSEcCtD
Naltrexone—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000737	0.000813	CcSEcCtD
Naltrexone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000736	0.000812	CcSEcCtD
Naltrexone—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000728	0.000804	CcSEcCtD
Naltrexone—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000715	0.000789	CcSEcCtD
Naltrexone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000711	0.000785	CcSEcCtD
Naltrexone—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000711	0.000785	CcSEcCtD
Naltrexone—UGT1A1—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000707	0.00908	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.000705	0.00905	CbGpPWpGaD
Naltrexone—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000702	0.000775	CcSEcCtD
Naltrexone—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000702	0.000775	CcSEcCtD
Naltrexone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000701	0.000774	CcSEcCtD
Naltrexone—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000688	0.000759	CcSEcCtD
Naltrexone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000684	0.000754	CcSEcCtD
Naltrexone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000684	0.000754	CcSEcCtD
Naltrexone—UGT1A1—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.00068	0.00873	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000678	0.00871	CbGpPWpGaD
Naltrexone—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000674	0.000744	CcSEcCtD
Naltrexone—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000674	0.000744	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000673	0.000742	CcSEcCtD
Naltrexone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00067	0.000739	CcSEcCtD
Naltrexone—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000663	0.000731	CcSEcCtD
Naltrexone—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00066	0.000729	CcSEcCtD
Naltrexone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000652	0.000719	CcSEcCtD
Naltrexone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000652	0.000719	CcSEcCtD
Naltrexone—UGT1A1—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000647	0.00831	CbGpPWpGaD
Naltrexone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000646	0.000712	CcSEcCtD
Naltrexone—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000642	0.000709	CcSEcCtD
Naltrexone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000639	0.000705	CcSEcCtD
Naltrexone—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000637	0.000702	CcSEcCtD
Naltrexone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00063	0.000695	CcSEcCtD
Naltrexone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00063	0.000695	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000629	0.00808	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	0.000625	0.00803	CbGpPWpGaD
Naltrexone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000617	0.000681	CcSEcCtD
Naltrexone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000616	0.000679	CcSEcCtD
Naltrexone—UGT1A1—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000613	0.00788	CbGpPWpGaD
Naltrexone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000606	0.000668	CcSEcCtD
Naltrexone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000606	0.000668	CcSEcCtD
Naltrexone—UGT1A1—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000601	0.00772	CbGpPWpGaD
Naltrexone—Rash—Formoterol—chronic obstructive pulmonary disease	0.000601	0.000663	CcSEcCtD
Naltrexone—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000601	0.000663	CcSEcCtD
Naltrexone—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.0006	0.000662	CcSEcCtD
Naltrexone—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.0006	0.000662	CcSEcCtD
Naltrexone—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.0006	0.000662	CcSEcCtD
Naltrexone—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000597	0.000659	CcSEcCtD
Naltrexone—Headache—Formoterol—chronic obstructive pulmonary disease	0.000597	0.000659	CcSEcCtD
Naltrexone—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000597	0.000658	CcSEcCtD
Naltrexone—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000596	0.000658	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.000596	0.00765	CbGpPWpGaD
Naltrexone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000595	0.000656	CcSEcCtD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000595	0.00764	CbGpPWpGaD
Naltrexone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000593	0.000655	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—CD8A—chronic obstructive pulmonary disease	0.000593	0.00762	CbGpPWpGaD
Naltrexone—Rash—Montelukast—chronic obstructive pulmonary disease	0.000589	0.000649	CcSEcCtD
Naltrexone—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000588	0.000649	CcSEcCtD
Naltrexone—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000587	0.000647	CcSEcCtD
Naltrexone—Depression—Prednisone—chronic obstructive pulmonary disease	0.000586	0.000647	CcSEcCtD
Naltrexone—Headache—Montelukast—chronic obstructive pulmonary disease	0.000585	0.000645	CcSEcCtD
Naltrexone—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.00058	0.00064	CcSEcCtD
Naltrexone—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000578	0.000638	CcSEcCtD
Naltrexone—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000576	0.000636	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000574	0.00737	CbGpPWpGaD
Naltrexone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000572	0.000631	CcSEcCtD
Naltrexone—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.00057	0.000629	CcSEcCtD
Naltrexone—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000567	0.000626	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000567	0.00729	CbGpPWpGaD
Naltrexone—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000567	0.000626	CcSEcCtD
Naltrexone—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000567	0.000625	CcSEcCtD
Naltrexone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000566	0.000625	CcSEcCtD
Naltrexone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000566	0.000625	CcSEcCtD
Naltrexone—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000564	0.000622	CcSEcCtD
Naltrexone—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000556	0.000613	CcSEcCtD
Naltrexone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000554	0.000612	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000552	0.00709	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.000551	0.00707	CbGpPWpGaD
Naltrexone—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000548	0.000604	CcSEcCtD
Naltrexone—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000546	0.000602	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000539	0.00693	CbGpPWpGaD
Naltrexone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000534	0.00059	CcSEcCtD
Naltrexone—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000532	0.000587	CcSEcCtD
Naltrexone—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000525	0.000579	CcSEcCtD
Naltrexone—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000519	0.000572	CcSEcCtD
Naltrexone—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000516	0.000569	CcSEcCtD
Naltrexone—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000516	0.000569	CcSEcCtD
Naltrexone—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000508	0.00056	CcSEcCtD
Naltrexone—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000504	0.000556	CcSEcCtD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000503	0.00646	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.0005	0.00642	CbGpPWpGaD
Naltrexone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000499	0.00055	CcSEcCtD
Naltrexone—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000493	0.000544	CcSEcCtD
Naltrexone—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000479	0.000528	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000477	0.00613	CbGpPWpGaD
Naltrexone—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000477	0.000526	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000473	0.00607	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00047	0.00604	CbGpPWpGaD
Naltrexone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000467	0.000515	CcSEcCtD
Naltrexone—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000466	0.000515	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000466	0.00599	CbGpPWpGaD
Naltrexone—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000463	0.000511	CcSEcCtD
Naltrexone—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000462	0.00051	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.00046	0.00591	CbGpPWpGaD
Naltrexone—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.00046	0.000507	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000456	0.00585	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000454	0.00583	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000451	0.00579	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000447	0.00575	CbGpPWpGaD
Naltrexone—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000441	0.000487	CcSEcCtD
Naltrexone—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000433	0.000478	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000428	0.0055	CbGpPWpGaD
Naltrexone—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000426	0.00047	CcSEcCtD
Naltrexone—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000425	0.000469	CcSEcCtD
Naltrexone—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000422	0.000466	CcSEcCtD
Naltrexone—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.00042	0.000463	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.00042	0.00539	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000417	0.00535	CbGpPWpGaD
Naltrexone—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000414	0.000457	CcSEcCtD
Naltrexone—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000412	0.000455	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000411	0.00527	CbGpPWpGaD
Naltrexone—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.00041	0.000452	CcSEcCtD
Naltrexone—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000404	0.000446	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.0004	0.00513	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.0004	0.00513	CbGpPWpGaD
Naltrexone—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000398	0.000439	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000398	0.00511	CbGpPWpGaD
Naltrexone—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000397	0.000438	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000395	0.00508	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000395	0.00507	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000392	0.00504	CbGpPWpGaD
Naltrexone—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000391	0.000432	CcSEcCtD
Naltrexone—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000391	0.000432	CcSEcCtD
Naltrexone—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.00039	0.00043	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000389	0.000429	CcSEcCtD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000387	0.00497	CbGpPWpGaD
Naltrexone—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000387	0.000426	CcSEcCtD
Naltrexone—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00038	0.00042	CcSEcCtD
Naltrexone—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000375	0.000414	CcSEcCtD
Naltrexone—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000375	0.000414	CcSEcCtD
Naltrexone—Infection—Prednisone—chronic obstructive pulmonary disease	0.000373	0.000411	CcSEcCtD
Naltrexone—Shock—Prednisone—chronic obstructive pulmonary disease	0.000369	0.000407	CcSEcCtD
Naltrexone—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000368	0.000406	CcSEcCtD
Naltrexone—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000366	0.000404	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000366	0.0047	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000365	0.00469	CbGpPWpGaD
Naltrexone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000364	0.000402	CcSEcCtD
Naltrexone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000363	0.0004	CcSEcCtD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000361	0.00463	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.00036	0.00462	CbGpPWpGaD
Naltrexone—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000357	0.000394	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000347	0.00445	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000346	0.00445	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000342	0.00439	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000342	0.000377	CcSEcCtD
Naltrexone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000341	0.000377	CcSEcCtD
Naltrexone—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000339	0.000374	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000338	0.00435	CbGpPWpGaD
Naltrexone—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000337	0.000372	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000336	0.00432	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000335	0.0043	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000334	0.00429	CbGpPWpGaD
Naltrexone—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000326	0.00036	CcSEcCtD
Naltrexone—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000325	0.000359	CcSEcCtD
Naltrexone—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000325	0.000359	CcSEcCtD
Naltrexone—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000323	0.000357	CcSEcCtD
Naltrexone—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000323	0.000357	CcSEcCtD
Naltrexone—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000321	0.000354	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—IL1B—chronic obstructive pulmonary disease	0.000315	0.00404	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000312	0.00401	CbGpPWpGaD
Naltrexone—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000309	0.000341	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000309	0.00396	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000307	0.000338	CcSEcCtD
Naltrexone—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000307	0.000338	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000304	0.00391	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000302	0.00388	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000299	0.00384	CbGpPWpGaD
Naltrexone—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000298	0.000329	CcSEcCtD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000297	0.00381	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000297	0.00381	CbGpPWpGaD
Naltrexone—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000296	0.000327	CcSEcCtD
Naltrexone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000296	0.000327	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000295	0.00379	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000293	0.00376	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000288	0.0037	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000279	0.00358	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000277	0.00355	CbGpPWpGaD
Naltrexone—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000276	0.000305	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000271	0.00348	CbGpPWpGaD
Naltrexone—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000269	0.000297	CcSEcCtD
Naltrexone—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000265	0.000293	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000265	0.0034	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000264	0.0034	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000261	0.00336	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000258	0.00331	CbGpPWpGaD
Naltrexone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000257	0.000283	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000252	0.00324	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000251	0.00322	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000249	0.0032	CbGpPWpGaD
Naltrexone—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000248	0.000274	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—TGFB1—chronic obstructive pulmonary disease	0.000245	0.00314	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000244	0.00313	CbGpPWpGaD
Naltrexone—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000238	0.000263	CcSEcCtD
Naltrexone—Rash—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000261	CcSEcCtD
Naltrexone—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000261	CcSEcCtD
Naltrexone—Headache—Prednisone—chronic obstructive pulmonary disease	0.000235	0.000259	CcSEcCtD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000233	0.00299	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000232	0.00298	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000232	0.00298	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.00023	0.00296	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000229	0.00294	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000229	0.00294	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000226	0.0029	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000224	0.00288	CbGpPWpGaD
Naltrexone—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000223	0.000246	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000214	0.00274	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000213	0.00274	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000211	0.00271	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.000205	0.00264	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000204	0.00262	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000203	0.00261	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000202	0.00259	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000201	0.00259	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000196	0.00252	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000194	0.00249	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000191	0.00245	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000185	0.00237	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000185	0.00237	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL6—chronic obstructive pulmonary disease	0.000184	0.00237	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.00018	0.00232	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.00018	0.00231	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GC—chronic obstructive pulmonary disease	0.00018	0.00231	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000179	0.0023	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000177	0.00227	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000172	0.00221	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000171	0.00219	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000171	0.00219	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.00017	0.00218	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000167	0.00215	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000164	0.00211	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000163	0.0021	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.00016	0.00206	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000156	0.00201	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000154	0.00198	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.000152	0.00196	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000151	0.00194	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000149	0.00192	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000146	0.00187	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000143	0.00184	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.000139	0.00178	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000135	0.00174	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000132	0.0017	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.00013	0.00167	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000128	0.00164	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000128	0.00164	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000127	0.00164	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000124	0.0016	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000124	0.0016	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000121	0.00156	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.000119	0.00153	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000118	0.00152	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000116	0.00149	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000114	0.00147	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000114	0.00147	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000114	0.00146	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000109	0.0014	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000109	0.0014	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000108	0.00139	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000104	0.00133	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000103	0.00133	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	9.98e-05	0.00128	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.81e-05	0.00126	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	9.8e-05	0.00126	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	9.7e-05	0.00125	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	9.64e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	9.22e-05	0.00118	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	9.22e-05	0.00118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.1e-05	0.00117	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	9.06e-05	0.00116	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	8.85e-05	0.00114	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	8.75e-05	0.00112	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.47e-05	0.00109	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.46e-05	0.00109	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	8.43e-05	0.00108	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	8.24e-05	0.00106	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.16e-05	0.00105	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	7.98e-05	0.00103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.81e-05	0.001	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.66e-05	0.000984	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	7.66e-05	0.000984	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.42e-05	0.000953	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.03e-05	0.000903	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.98e-05	0.000896	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	6.85e-05	0.00088	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.85e-05	0.00088	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.8e-05	0.000874	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	6.74e-05	0.000866	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.71e-05	0.000862	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	6.57e-05	0.000844	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.38e-05	0.00082	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.34e-05	0.000815	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	6.29e-05	0.000807	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	6.27e-05	0.000805	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.25e-05	0.000803	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.16e-05	0.000792	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	6.16e-05	0.000792	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.12e-05	0.000786	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.1e-05	0.000784	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.93e-05	0.000761	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	5.87e-05	0.000754	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	5.79e-05	0.000743	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.67e-05	0.000729	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.6e-05	0.000719	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.56e-05	0.000714	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.35e-05	0.000688	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	5.21e-05	0.000669	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	5.17e-05	0.000665	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.17e-05	0.000664	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.98e-05	0.000639	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.73e-05	0.000608	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.7e-05	0.000604	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.67e-05	0.000599	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.52e-05	0.000581	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.5e-05	0.000578	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.45e-05	0.000572	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	4.45e-05	0.000572	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.25e-05	0.000546	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.21e-05	0.00054	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.09e-05	0.000526	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	4.06e-05	0.000522	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—chronic obstructive pulmonary disease	4.03e-05	0.000517	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.95e-05	0.000507	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.9e-05	0.000502	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.85e-05	0.000495	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.77e-05	0.000484	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.74e-05	0.000481	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.73e-05	0.000479	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.59e-05	0.000461	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.46e-05	0.000444	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.41e-05	0.000438	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.31e-05	0.000425	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.3e-05	0.000424	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.15e-05	0.000405	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.14e-05	0.000404	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.12e-05	0.000401	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.08e-05	0.000395	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.06e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.99e-05	0.000384	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.87e-05	0.000368	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.81e-05	0.000361	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.79e-05	0.000359	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.76e-05	0.000354	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.72e-05	0.000349	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.69e-05	0.000345	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.66e-05	0.000341	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.53e-05	0.000325	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.47e-05	0.000317	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.42e-05	0.00031	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.31e-05	0.000297	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.27e-05	0.000292	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.12e-05	0.000272	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.08e-05	0.000268	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.04e-05	0.000262	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.03e-05	0.000261	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.86e-05	0.000239	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.85e-05	0.000237	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.77e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.72e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.57e-05	0.000202	CbGpPWpGaD
